The Return Of Martin Shkreli
This article was originally published in Start Up
Biotech entrepreneur Martin Shkreli hopes to recreate his Retrophin success with his new venture, Turing Pharmaceuticals, but can he dodge past potholes as he seeks to raise venture capital?
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.